After 13 years at the helm of the UK’s BioIndustry Association, Steve Bates has tendered his resignation as chief executive ...

Scancell Holdings, the developer of Immunobody and Moditope active immunotherapies to treat cancer, has announced further positive data from the ongoing Phase II SCOPE trial of SCIB1/iSCIB1+ ...

Patients in the UK will now be able to access advanced, personalized treatments prepared at the hospital or even in mobile ...

Swiss pharma Sandoz (SIX: SDZ) has spent less than a year charting its course as an independent company, but already it’s ...

Shares in Replimune Group, a US biotech developing novel oncolytic immunotherapies, went in freefall Tuesday, as the company ...

Cambridge, USA-based biotech Avalyn Pharma, which developing inhaled therapies for the treatment of life-threatening pulmonary diseases, has announced the closing of an oversubscribed $100 million ...

French pharma Ipsen (Euronext: IPN) today announced the following changes to its executive committee: Mari Scheiffele is appointed executive vice president (EVP) , chief product officer, Andreas ...

Shares of French clinical-stage biotech Abivax were up an astonishing 389% at 43.55 euros in early trading, after, late yesterday, it announced positive top-line results from its Phase III ABTECT-1 ...

French biotech ImCheck Therapeutics has announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its lead program, ICT01, a humanized anti-butyrophilin 3A (BTN3A ...

Neuraxpharm Group, a privately-held German specialty pharma focused on central nervous system (CNS) disorders, today announced the launch of a new affiliate, Neuraxpharm Australia, led by newly ...